Key Highlights
- Phase 1 cohorts 1-3 data for [212Pb]VMT-α-NET due October 23 at ESMO.
- Candidate targets neuroendocrine tumors using a lead-212 radiopharmaceutical.
- Company plans further data submissions at conferences in 2026 and 2027.
- Isoray shares trade near $2.99, with a market value of about $341 million.
Isoray (NASDAQ: CATX) is scheduled to present Phase 1 data covering cohorts 1 through 3 for its radiopharmaceutical candidate [212Pb]VMT-α-NET in neuroendocrine tumors at the ESMO 2026 congress on October 23.
What Happened
The candidate is being developed as a targeted radiopharmaceutical therapy for neuroendocrine tumors, using lead-212 as the radioactive component.
The company said it plans to submit additional data for presentation at future medical conferences in 2026 and 2027, beyond the initial ESMO presentation.
Market Reaction
Isoray, a small-cap company valued at approximately $341 million, traded near $2.99 per share, up $0.04, or 1.36%, according to the disclosed pipeline database.
Outlook
Phase 1 cohort 1-3 data is scheduled for presentation at ESMO on October 23, 2026, with additional data submissions planned for conferences in 2026 and 2027.
What is [212Pb]VMT-α-NET?
It is a radiopharmaceutical candidate using lead-212 being developed by Isoray for neuroendocrine tumors.
When will Isoray present its Phase 1 data?
Phase 1 cohorts 1-3 data is scheduled for presentation at the ESMO 2026 congress on October 23.
Does Isoray plan further data releases?
Yes. The company said it plans to submit additional data for presentation at future medical conferences in 2026 and 2027.






Please wait processing your request...